New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

From: GRACEcast
0 0 5 years ago
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

Find us on Facebook